Bisphenol A, Chlorinated Derivatives of Bisphenol A and Occurrence

Jul 16, 2019 - This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. Read th...
0 downloads 0 Views 331KB Size
Subscriber access provided by KEAN UNIV

Ecotoxicology and Human Environmental Health

Bisphenol A, chlorinated derivatives of Bisphenol A and occurrence of myocardial infarction in patients with type 2 diabetes: nested case-control studies in two European cohorts Chunyun Hu, Ben Schöttker, Nicolas Venisse, Frederike Limousi, Pierre Jean Saulnier, Marion Albouy-Llaty, Antoine DUPUIS, Hermann Brenner, Virginie Migeot, and Samy Hadjadj Environ. Sci. Technol., Just Accepted Manuscript • DOI: 10.1021/acs.est.9b02963 • Publication Date (Web): 16 Jul 2019 Downloaded from pubs.acs.org on July 18, 2019

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 24

Environmental Science & Technology

1

Bisphenol A, chlorinated derivatives of Bisphenol A and occurrence of myocardial infarction

2

in patients with type 2 diabetes: nested case-control studies in two European cohorts

3

Chunyun Hu *1,2,3, Ben Schöttker *4,5, Nicolas Venisse 3,6, Frédérike Limousi 1,2,3, Pierre Jean

4

Saulnier 2,3, Marion Albouy-Llaty 1,2,3, Antoine Dupuis 2, 3, 7, Hermann Brenner *4,5, Virginie

5

Migeot *1,2,3, Samy Hadjadj *2,3,8,9

6 7

1 CHU

Poitiers, Department of Public Health, F-86021 Poitiers, France

8

2 Université de Poitiers, School of Medicine and

9

3 INSERM

Pharmacy of Poitiers, F-86073 Poitiers, France

CIC 1402, CHU Poitiers, F-86021 Poitiers, France

Division of Clinical Epidemiology and Aging Research, Division of Preventive Oncology,

10

4

11

German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany

12

5

Network Aging Research, D-69115 Heidelberg, Germany

13

6

CHU Poitiers, Department of Toxicology and Pharmacokinetics, F-86021 Poitiers, France

14

7

CHU Poitiers, Department of Pharmacy, F-86021 Poitiers, France

15

8

CHU Poitiers, Department of Endocrinology, F-86021 Poitiers, France

16

9

L’institut du thorax, INSERM, CNRS, Univ Nantes, CHU Nantes, F-44093 Nantes, France

17 18

*These authors equally contributed to the present manuscript

19

Correspondence to : V Migeot : [email protected]

20

CHU Poitiers, Department of Public Health, 2 rue de la Milétrie, F-86021 Poitiers, France

21 22

Key words: Bisphenol A – Chlorinated derivatives of bisphenol A- Myocardial infarction – Type 2

23

diabetes.

24

ACS Paragon Plus Environment

Environmental Science & Technology

25

ABSTRACT

26

A positive association between Bisphenol A (BPA) exposure and coronary heart disease has

27

been shown, but not in patients with type 2 diabetes (T2D). During the treatment of drinking

28

water, chlorination leads to the formation of chlorinated derivatives of Bisphenol A (ClxBPA),

29

that have higher estrogenic activity than BPA. No evidence exists for a relationship between

30

exposure to ClxBPA and myocardial infarction in patients with T2D. The objective of this study

31

was to evaluate the relationship between exposure to BPA, ClxBPA and the occurrence of

32

myocardial infarction (MI) in patients with T2D. Two nested case-control studies in two

33

independent European cohorts were performed. Each case with incident MI during follow-up

34

was matched to one control on age, sex and personal cardiovascular history in the same

35

cohort. Association between baseline urine concentrations of BPA and of ClxBPA and incident

36

MI was determined. Exposure to BPA was 31% in the ESTHER cohort and 18% in the

37

SURDIAGENE cohort. In a meta-analysis of the two studies, occurrence of MI was significantly

38

associated with urine BPA detection: adjusted OR=1.97 (1.05; 3.70), p=0.04. Exposure to

39

ClxBPA significantly differed in the SURDIAGENE and ESTHER studies: 24% and 8%, respectively

40

(p=0.0003). It was very strongly associated with MI in the SURDIAGENE cohort with an

41

adjusted odds ratio (OR) of 14.15 (95% confidence interval: 2.77 - 72.40) but this association

42

was not replicated in the ESTHER study: adjusted OR: 0.17 (0.02 to 1.23). Whether these

43

results may be explained by different water chlorination processes in France and Germany,

44

resulting in different ClxBPA exposure levels, requires further investigation.

45

ACS Paragon Plus Environment

Page 2 of 24

Page 3 of 24

Environmental Science & Technology

46

INTRODUCTION

47

People with diabetes mellitus (DM) represent a large and growing population worldwide. It has been

48

shown that diabetes increases the risk of coronary heart disease (CHD) 1 and mortality after a first

49

myocardial infarction (MI) 2. People with type 2 diabetes (T2D) are prone to cardiovascular disease

50

(CVD), including MI, and the risk of CHD mortality has been suggested to be equivalent in patients with

51

T2D with no history of MI to the risk in non-diabetes persons with a history of MI 3. The possible

52

contribution to this increased risk of environmental factors such as endocrine disruptors has yet to be

53

established. Patients with T2D risk can be seen as a group of peculiar interest for the identification of

54

environmental factors related to cardiovascular complications.

55 56

Bisphenol A (BPA) is a synthetic monomer considered as an endocrine-disrupting chemical inasmuch

57

as it exhibits estrogenic activity 4. The general population in Western countries is exposed to and/or at

58

risk from exposure to BPA 5. Exposure is ubiquitous in daily life, mainly through packaged food and

59

beverages contaminated by BPA and migrating from the packaging material 67. During the treatment

60

of drinking water, chlorination can easily lead to the formation of chlorinated derivatives of BPA,

61

resulting in production of monochloro-bisphenol A (MCBPA), dichloro-bisphenol A (DCBPA), trichloro-

62

bisphenol A (TCBPA) and tetrachloro-bisphenol A (TTCBPA). Human exposure to chlorinated

63

derivatives of BPA mainly originates from drinking water, except for TTCBPA, which is used as a flame-

64

retardant 8. Several studies have demonstrated, in vitro or in vivo, higher estrogenic activity with

65

chlorinated derivatives than with BPA, especially MCBPA and DCBPA

66

proliferator-activated receptor gamma (PPAR) agonist effect

67

separate environmental sources and could translate into different health risks. Evidence for the

68

association of BPA with T2D has been inconsistent in human studies 12 13 14 15. Notwithstanding a recent

69

meta-analysis suggesting a positive association between urinary concentration of BPA and CVD/CHD

70

16,

71

particularly in patients with T2D. Recently, Andra showed a weak positive association between urinary

11.

9 10,

and also a peroxisome

ClxBPA and BPA probably reflect

we still lack consolidated clinical evidence of the association between BPA exposure and CVD/CHD,

ACS Paragon Plus Environment

Environmental Science & Technology

72

mono-chloro-BPA and obesity 17 or with T2D 18. To our knowledge, no previous study has investigated

73

the relationship between exposure to ClxBPA and CVD/CHD, either in the general population or in T2D

74

patients.

75 76

We consequently evaluated the relationship between exposure to BPA and ClxBPA and the risk of

77

myocardial infarction SURDIAGENE cohort

78

German ESTHER cohort as a replication step 20.

19

as a discovery step, and in T2D participants from the

79 80

METHODS

81

Design: We performed a nested case-control study in the SURDIAGENE cohort (discovery step) and in

82

the ESTHER cohort (replication step).

83 84

Settings and participants:

85

SURDIAGENE discovery cohort: The SURDIAGENE study is a French single-center inception cohort of

86

T2D patients regularly visiting the diabetes department at Poitiers University Hospital, France (23),

87

including 1,468 participants. Patients were enrolled from 2002 to 2012. Main recruiting criteria were

88

type 2 diabetes, registration to the French social security and no evidence of non-diabetic renal

89

disease. The current report considered adjudicated outcomes, with median follow-up time for the

90

whole cohort of 6.4 years, as previously published 19. Study outcome updates were performed every 2

91

years since 2007. The data from 2013 were considered for the current analysis. Vital status was

92

ascertained using the French death registry (CepiDC). The cause of death was specified according to

93

hospital discharge information and/or interview of the GP and/or interrogation of the CepIDC. Fatal

94

MI was considered for death coded with ICD-10 codes I21-I23. The Poitiers University Hospital Ethics

95

Committee approved the design (CPP Ouest III). All participants in the study gave their informed

96

written consent 19 and the study was conducted in accordance with the Declaration of Helsinki.

97

ACS Paragon Plus Environment

Page 4 of 24

Page 5 of 24

Environmental Science & Technology

98

ESTHER replication cohort: ESTHER is an ongoing population-based cohort study including 9,949 older

99

adults resident in the state of Saarland, Germany, described in detail elsewhere 21. In brief, participants

100

were recruited between July 2000 and December 2002 by their general practitioner (GP) during a

101

regular health check-up. Inclusion criteria were residence in the state of Saarland, age between 50 and

102

74 years, and sufficient knowledge of the German language. The current report focuses on 1,375

103

ESTHER participants with physician-diagnosed T2D at baseline 20. Follow-up questionnaires, including

104

information on incident MI, were sent to study participants and their GPs after 2, 5 and 8 years with

105

response rates among survivors of 96%, 87% and 79%, respectively. Fatal MI events between 2000 and

106

2010 were identified by inquiry at the residents’ registration offices in Saarland and information on

107

the vital status could be obtained for 99.9% of the ESTHER participants. Death certificates were

108

provided for 97.7% of deceased participants by public health departments. Fatal MI events were

109

identified by deaths coded with ICD-10 codes I21-I23. The ESTHER study was approved by the Ethics

110

Committees of the Medical Faculty, University of Heidelberg and by the Medical Association of

111

Saarland and was conducted in accordance with the Declaration of Helsinki. Written informed consent

112

was obtained from all participants.

113

Sample size calculation: For the discovery cohort all patients from the Surdiagene study presenting a

114

myocardial infarction were included, as cases. Based on the study from Liao and Kannan 22, exposure

115

to Clx-BPA was estimated to be 20%. Then, using one control for each case enables to detect, at 95%

116

probability, an association between exposure to Clx-BPA and MI with an estimated Odds Ratio equal

117

to 2.53. Due to high cost of the assay, increasing the control-to-case ratio was not possible. Similar

118

hypotheses were used for sample size calculation for the replication cohort.

119

Participants: In the SURDIAGENE cohort, cases were defined as all eligible participants with T2D who

120

developed myocardial infarction during the follow-up period (2002-2013). MI was defined according

121

to the universal definition 23 with adjudication by an independent clinical outcome committee in the

122

SURDIAGENE cohort (see composition in appendix). In the ESTHER cohort, self-reported MI was only

123

considered as a case if it was confirmed by medical records from the study participants' GP. In addition,

ACS Paragon Plus Environment

Environmental Science & Technology

124

MIs recorded in death certificates were considered as cases. Of note, we considered both first-

125

occurring and recurrent MI during follow-up for the SURDIAGENE participants, while only first-

126

occurring MI was used for the ESTHER participants.

127 128

Controls were selected by incidence density sampling, which involved matching each case to a sample

129

of those who were at risk at the time of case occurrence 24. We chose one control with T2D for each

130

case, matched on age (± 3 years), sex, and personal history of cardiovascular disease at study entry

131

(stroke or MI for the SURDIAGENE and stroke for the ESTHER study participants). The main exclusion

132

criteria for both nested case-control studies were: no available baseline urine sample and estimated

133

glomerular filtration rate (eGFR) < 30 ml/min/1.73m2). In addition, in the ESTHER study, subjects with

134

a history of MI before baseline were excluded. After inclusion of cases and controls, some urine

135

samples were unfortunately damaged leading to the exclusion of 11 case-control pairs in the ESTHER

136

study. The baseline spot urine samples of all the eligible participants of the two studies were collected

137

and stored at -80°C. The SURDIAGENE samples were stored and handled at the CHU Poitiers biobank

138

(CRB BB0033-00068). We collected the main confounding factors at baseline that may influence the

139

occurrence of MI. Variables included were smoking (from self-reported status as non-smoker vs.

140

current or former smoker), body mass index, systolic and diastolic pressure, total plasma cholesterol,

141

LDL-cholesterol, HDL-cholesterol, Triglycerids, HbA1C, and glomerular filtration rate (MDRD).

142

Assessment of BPA and ClxBPA exposure: Three hundred microliters of urine sample were used for

143

analysis, after storage at -80°C at CRB, CHU de Poitiers: Biobanking facility BB0033-00068. Urine

144

concentrations of unconjugated BPA, MCBPA, DCBPA, TCBPA and TTCBPA were measured by the same

145

laboratory in Poitiers University Hospital using Liquid Chromatography-tandem Mass Spectrometry

146

technology. Technicians were blinded for the case/control status. The limits of detection (LOD) were

147

0.25 and 0.025 ng/mL for BPA and ClxBPA, respectively. The limits of quantification (LOQ) were 0.5 and

148

0.05 ng/mL for BPA and ClxBPA, respectively 25. It means that when above the LOQ (0.05 ng/mL), the

ACS Paragon Plus Environment

Page 6 of 24

Page 7 of 24

Environmental Science & Technology

149

concentration can be determined with adequate accuracy and precision while when below the LOQ

150

(0.025 ng/mL), one can guarantee with a 95% level of confidence

151

that the compound is present but its concentration cannot be determined with adequate accuracy and

152

precision. Otherwise when below the LOD (LOD (%)

P

BPA

30 (18.1%)

19 (22.9%)

11 (13.2%)

0.15

CBPA

18 (10.8%)

16 (19.3%)

2 (2.4%)

0.0007

DCBPA

20 (12.0%)

16 (19.3%)

4 (4.8%)

0.007

TCBPA

24 (14.5%)

20 (24.1%)

4 (4.8%)

0.0006

TTCBPA

33 (19.9%)

30 (36.1%)

3 (3.6%)